| Oct 30 |
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
|
| Oct 29 |
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
|
| Oct 28 |
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
|
| Oct 21 |
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
|
| Oct 12 |
Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy
|
| Oct 10 |
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
|
| Oct 9 |
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
|
| Oct 8 |
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
|
| Sep 27 |
Aditx Therapeutics announces 1-for-40 reverse stock split for Nasdaq compliance
|
| Sep 27 |
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
|
